Jci_page_head_homepage_01 Jci_page_head_homepage_02
Thomas J. Scriba, Hua-Tang Zhang, Helen L. Brown, Annette Oxenius, Norbert Tamm, Sarah Fidler, Julie Fox, Jonathan N. Weber, Paul Klenerman, Cheryl L. Day, Michaela Lucas, Rodney E. Phillips
Published in Volume 115, Issue 2
J Clin Invest. 2005; 115(2):443–450 doi:10.1172/JCI23084
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 7

HIV-specific tetramer+ CD4+ cells in untreated chronic patients resemble those in viremic patients who received short-course ART at acute infection. (A) Longitudinal detection of tetramer+ CD4+ cells up to 63 weeks and 85 weeks after the first experience of seroconversion symptoms in patients Ox22 and Ox79, respectively. The frequency of tetramer+ CD4+ cells for each time point is indicated in the upper-right quadrant of each plot. (B) Phenotypic analysis of tetramer+ CD4+ cells from patient Ox79. These analyses were performed at time points 52 weeks or more after the first experience of seroconversion symptoms. The percentage of tetramer+ CD4+ cells expressing the relevant marker is indicated in parentheses in each plot.